PNT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 gruod. 2023 @ 23:00):

Stats
Dzisiejszy wolumen	3.29M
Średni wolumen	3.85M
Kapitalizacja rynkowa	1.33B
EPS	$0 ( 2024-03-25 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	11.36
ATR14	$0.322 (2.58%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Goodman Jonathan R.	Sell	41 872	Common Stock
2023-12-27	Goodman Jonathan R.	Sell	35 872	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 000	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 614	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	44 749	Stock Option (Right to Buy)

INSIDER POWER
-78.10
Last 96 transactions
Buy: 3 517 450 \| Sell: 10 366 533

Wolumen Korelacja

Długi: 0.24 (neutral)

Krótki: -0.64 (weak negative)

Signal:(35.382) Neutral

POINT Biopharma Global Korelacja

10 Najbardziej pozytywne korelacje
THRX	0.965
SUMR	0.964
CVLT	0.955
MSVB	0.953
TESS	0.947
BRAC	0.937
TACO	0.934
GHSI	0.933
NGM	0.931
VERA	0.93

10 Najbardziej negatywne korelacje
TKLF	-0.933
LSAQ	-0.933
EXTR	-0.929
CYXT	-0.918
SMPL	-0.913
GOVX	-0.912
MRBK	-0.911
MPB	-0.91
COLB	-0.91
SINT	-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

POINT Biopharma Global Korelacja - Waluta/Towar

0.43
( neutral )

0.66
( moderate )

-0.26
( neutral )

0.34
( neutral )

0.47
( neutral )

-0.67
( moderate negative )

POINT Biopharma Global Finanse

Annual	2022
Przychody:	$226.58M
Zysk brutto:	$226.58M (100.00 %)
EPS:	$1.040

FY	2022
Przychody:	$226.58M
Zysk brutto:	$226.58M (100.00 %)
EPS:	$1.040

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.181

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.00801

Financial Reports:

No articles found.

POINT Biopharma Global

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.